Literature DB >> 466654

Effect of a forced diuresis on the distribution and excretion (via urine and bile) of 195mplatinum when given as 195mplatinum cis-dichlorodiammineplatinum(II).

P A DeSimone, R S Yancey, J J Coupal, J D Butts, J D Hoeschel.   

Abstract

195mPlatinum cis-dichlorodiammineplatinum(II) (195mPt cis-DDP) was injected iv with furosemide or mannitol into male Sprague-Dawley rats. The effect of such a diuresis on the distribution, excretion, and retention of cis-DDP was measured. The mannitol-treated animals had a significant increase in the urinary excretion of 196mPt over control animals for the first five 15-minute collection times and for the 24-hour cumulative urine for the 0.01-mg/kg dose. At the 6-mg/kg dose, only the first three 15-minute and 24-hour cumulative urine collections were significant. This increased excretion, however, did not affect tissue or blood concentrations of this agent. Furosemide did not affect the excretion of 195mPt. A biliary excretion of 195mPt given as 195mPt cis-DDP is documented. The excretion is biphasic, with a rapid phase followed by a slower protracted phase. Forced diuresis, if it affords renal protection, does so during the first 90 minutes of urinary excretion.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 466654

Source DB:  PubMed          Journal:  Cancer Treat Rep        ISSN: 0361-5960


  10 in total

Review 1.  Cisplatinum: a review, with special reference to cellular and molecular interactions.

Authors:  C L Litterst
Journal:  Agents Actions       Date:  1984-12

2.  Biliary excretion of platinum in a patient treated with cis-dichlorodiammineplatinum (II).

Authors:  M D Shelley; R G Fish; M Adams
Journal:  Antimicrob Agents Chemother       Date:  1985-02       Impact factor: 5.191

Review 3.  Platinum antitumour agents: a review of (bio)analysis.

Authors:  T J Hodes; W J Underberg; G Los; J H Beijnen
Journal:  Pharm Weekbl Sci       Date:  1992-06-19

4.  Effects of the diuretics mannitol or acetazolamide on nephrotoxicity and physiological disposition of cisplatin in rats.

Authors:  N M Osman; M P Copley; C L Litterst
Journal:  Cancer Chemother Pharmacol       Date:  1984       Impact factor: 3.333

5.  Physiological model for the pharmacokinetics of cis-dichlorodiammineplatinum (II) (DDP) in the tumored rat.

Authors:  F F Farris; F G King; R L Dedrick; C L Litterst
Journal:  J Pharmacokinet Biopharm       Date:  1985-02

6.  Factors affecting human autopsy kidney-cortex and kidney-medulla platinum concentrations after cisplatin administration.

Authors:  D J Stewart; C Dulberg; J M Molepo; N Z Mikhael; V A Montpetit; M D Redmond; R Goel
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

7.  Physiological pharmacokinetic modeling of cis-dichlorodiammineplatinum(II) (DDP) in several species.

Authors:  F G King; R L Dedrick; F F Farris
Journal:  J Pharmacokinet Biopharm       Date:  1986-04

8.  Comparative distribution and excretion of carboplatin and cisplatin in mice.

Authors:  Z H Siddik; M Jones; F E Boxall; K R Harrap
Journal:  Cancer Chemother Pharmacol       Date:  1988       Impact factor: 3.333

9.  A comparative study of the distribution in the male rat of platinum-labelled cis-dichlorodiammine platinum (II), cis-trans-dichlorodihydroxy-bis-(isopropylamine) platinum (I), and cis-dichloro-bis-cyclopropylamine platinum (II).

Authors:  R Harrison; C A McAuliffe; A Zaki; J Baer; H Sharma; A Smith; H Jackson; B W Fox
Journal:  Cancer Chemother Pharmacol       Date:  1983       Impact factor: 3.333

Review 10.  Comparative adverse effect profiles of platinum drugs.

Authors:  M J McKeage
Journal:  Drug Saf       Date:  1995-10       Impact factor: 5.606

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.